Table 1:
Patient demographics of neoadjuvant chemoradiation and primary resection groups
| Treatment group |
|||
|---|---|---|---|
| Variables | Primary resection | Neoadjuvant chemoradiation | P-value |
| Number | 38 | 46 | |
| Age (years) | |||
| Mean ± SD | 62.0 ± 11.4 | 56.5 ± 8.4 | 0.01 |
| Range | 44–83 | 40–79 | |
| Sex | |||
| Male | 36 | 46 | 0.16 |
| Female | 2 | 0 | |
| Performance status | |||
| ECOG 0 | 36 | 45 | 0.54 |
| ECOG 1 | 1 | 1 | |
| ECOG 2 | 1 | 0 | |
| Location | |||
| Upper third | 4 | 8 | 0.04 |
| Middle third | 14 | 26 | |
| Lower third | 20 | 12 | |
| Endoscopic tumour length (cm) | |||
| Mean ± SD | 5.7 ± 2.4 | 6.2 ± 3.5 | 0.53 |
| Clinical TNM stage | |||
| T1N(+) | 1 | 4 | 0.07 |
| T2N(+) | 7 | 11 | |
| T3N(−) | 13 | 4 | |
| T3N(+) | 16 | 24 | |
| T4N(−) | 0 | 2 | |
| T4N(+) | 1 | 1 | |
| Total number of resected lymph nodesa | |||
| Mean ± SD | 25.3 ± 12.7 | 23.3 ± 19.0 | 0.59 |
| Range | 4–57 | 5–96 | |
| Pathological T stagea | |||
| T0 | 0 | 9 | 0.001 |
| T1 | 3 | 5 | |
| T2 | 5 | 8 | |
| T3 | 29 | 10 | |
| T4 | 1 | 2 | |
| Pathological N stagea | |||
| N0 | 16 | 18 | 0.71 |
| N1 | 13 | 11 | |
| N2 | 8 | 4 | |
| N3 | 1 | 1 | |
| Pathological stagea | |||
| Stage 0 | 0 | 7 | <0.001 |
| Stage I | 2 | 4 | |
| Stage II | 16 | 13 | |
| Stage III | 20 | 5 | |
| Stage IV | 0 | 5 | |
ECOG: Eastern Cooperative Oncology Group performance status.
aIn the neoadjuvant chemoradiation group, data were available for 34 patients who completed surgical resection.